Blood Cancer

Archer® Blood Cancer tests detect various driver mutations in hematologic malignancies, such as myeloid and lymphoid diseases, by targeted next-generation sequencing (NGS). This approach combines FusionPlex® and VariantPlex® panels to characterize gene fusions, copy number variations (CNVs) and other variants from a single sample.
Key Features
Unified Workflow

All Archer panels are powered by Anchored Multiplex PCR (AMP™) chemistry and thus follow the same workflow for maximum lab efficiency.

Comprehensive Mutation Profiling

Get the most information from your sample - fusions, CNVs, single-nucleotide variants (SNVs), indels and expression levels.

Complex Mutation Detection

Complete coverage combined with powerful bioinformatics enable detection of traditionally difficult regions like CEBPA & FLT3-ITDs.

Confident Mutation Calling

Powerful bioinformatics combined with orthogonal mutation verification.

Blood Cancer Panels

Catalog panels that are on the shelf and ready for delivery

RNA Input

  • 87 Genes
  • 1.5M Reads
  • 125 Genes
  • 2M Reads
  • 84 Genes
  • 1.5M Reads
  • 199 Genes
  • 4.5M Reads

DNA Input

  • 37 Genes
  • 3M Reads
  • 75 Genes
  • 4M Reads
Predesigned panels that can be delivered in 3-4 weeks

RNA Input

  • 9 Genes
  • 500K Reads

DNA Input

  • 11 Genes
  • 750K Reads

FLT3-ITD Detection

Open-ended amplification with defined read structure allows for de novo assembly and robust ITD detection of all sizes and integration sites.

FLT3 Detection

Internal tandem duplications (ITDs) in FLT3 are common oncogenic drivers in acute myeloid leukemia (AML) which often coexist with other types of driver mutations. Although NGS simultaneously detects multiple mutation types in a single sample, ITDs pose unique challenges to NGS methods, in part because of their highly variable nature and the difficulties of mapping repeated sequences to a wild-type reference. Anchored Multiplex PCR (AMP) technology permits complete, bidirectional coverage of ITD-containing regions, and the Archer Analysis pipeline enables de novo assembly of sequencing reads to generate a consensus sequence. As shown in the figure above, AMP-based NGS in combination with Archer Analysis enabled FLT3-ITD detection from blood samples in concordance with capillary gel electrophoresis (CGE), the current gold standard method for ITD detection.

High-complexity coverage across CEBPA

De-duplication of reads allows for true coverage information – i.e. the reported coverage depth represents the number of unique input molecules that were captured and sequenced, not the number of PCR duplicates that were sequenced. VariantPlex Myeloid panels are designed to have maximum unique molecule coverage across all targeted genes, including challenging regions like CEPBA, DNMT3A and RUNX1.

CEBPA contains 75% GC content over its coding region, making amplification and sequencing of the region challenging. Anchored Multiplex PCR (AMP) technology is well suited for amplification of this region due to flexible primer design strategies. Unlike opposing primer–based techniques, only one primer location needs to be designed. These primers are independent and can be moved around to give the best chance of amplification across the gene. Additionally, since Archer libraries and mutation calls are based on unique reads rather than PCR duplicates, variant calling can be made with library-specific knowledge of sensitivity.

Complete, strand-specific and bidirectional coverage of target exons,
including traditionally difficult regions like CEBPA.

Complex CEBPA Computer

This website stores cookies on your computer. These cookies are used to improve your website and provide more personalized services to you, both on this website and through other media. To find out more about the cookies we use, see our Privacy Policy.

We won’t track your information when you visit our site. But in order to comply with your preferences, we’ll have to use just one tiny cookie so that you’re not asked to make this choice again.